Literature DB >> 16424739

Antithrombotic therapies for sepsis: a need for more studies.

Peter C Minneci, Katherine J Deans, Xizhong Cui, Steven M Banks, Charles Natanson, Peter Q Eichacker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16424739     DOI： 10.1097/01.ccm.0000199035.29165.a7

Source DB:  PubMed          Journal:  Crit Care Med        ISSN： 0090-3493            Impact factor:   7.598


× No keyword cloud information.
  11 in total

Review 1.  The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death.

Authors:  Ping Qiu; Xizhong Cui; Amisha Barochia; Yan Li; Charles Natanson; Peter Q Eichacker
Journal:  Expert Opin Investig Drugs       Date:  2011-10-01       Impact factor: 6.206

2.  Mechanisms of sepsis and insights from clinical trials.

Authors:  Nitin Seam; Anthony F Suffredini
Journal:  Drug Discov Today Dis Mech       Date:  2007

3.  How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? A Bayesian design.

Authors:  Andre C Kalil; Junfeng Sun
Journal:  Intensive Care Med       Date:  2008-05-27       Impact factor: 17.440

4.  Association of prior antiplatelet agents with mortality in sepsis patients: a nationwide population-based cohort study.

Authors:  Min-Juei Tsai; Shuo-Ming Ou; Chia-Jen Shih; Pei-Wen Chao; Lan-Fu Wang; Yu-Ning Shih; Szu-Yuan Li; Shu-Chen Kuo; Yen-Tao Hsu; Yung-Tai Chen
Journal:  Intensive Care Med       Date:  2015-04-01       Impact factor: 17.440

5.  Fluid resuscitation targeting sepsis-induced cardiovascular dysfunction: severity of disease as effect modifier.

Authors:  Christian J Wiedermann; Stefan Dunzendorfer
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

Review 6.  The effect of heparin administration in animal models of sepsis: a prospective study in Escherichia coli-challenged mice and a systematic review and metaregression analysis of published studies.

Authors:  Yan Li; Jun-Feng Sun; Xizhong Cui; Haresh Mani; Robert L Danner; Xuemei Li; Jun-Wu Su; Yvonne Fitz; Peter Q Eichacker
Journal:  Crit Care Med       Date:  2011-05       Impact factor: 7.598

7.  Is antithrombin treatment of disseminated intravascular coagulation a quixotic goal?

Authors:  Nitin Seam; Anthony F Suffredini
Journal:  Crit Care       Date:  2014-11-25       Impact factor: 9.097

8.  Antithrombosis Trials: Should we test therapeutic heparin adjusted based on activated partial thromboplastin time in septic shock?

Authors:  Amisha V Barochia; Yan Li; Xizhong Cui; Daniel A Sweeney; Charles Natanson; Peter Q Eichacker
Journal:  Crit Care Med       Date:  2009-04       Impact factor: 7.598

Review 9.  Can we predict the effects of NF-kappaB inhibition in sepsis? Studies with parthenolide and ethyl pyruvate.

Authors:  Xuemei Li; Junwu Su; Xizhong Cui; Yan Li; Amisha Barochia; Peter Q Eichacker
Journal:  Expert Opin Investig Drugs       Date:  2009-08       Impact factor: 6.206

Review 10.  Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options.

Authors:  Peter S Maclean; R Campbell Tait
Journal:  Drugs       Date:  2007       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.